Jan 1 2021


BioTheryX, Inc. renews its confidence with INOVOTION for preclinical in vivo efficacy evaluation of their compounds.



For BioTheryX, Inc., a clinical-stage biopharmaceutical company focused on restoring protein homeostasis

through protein modulation, 2020 has been a fruitful year!


The company launched a Phase 1 Clinical Trial of BTX-A51 in January and announced a $35 Million

Series D financing in July.


We are proud to contribute to BioTheryX, Inc. preclinical efforts!

If you also wish to collaborate with us, please, feel free to  Contact us

All our news

All our webinars